Sakar Healthcare

Why is Sakar Healthcare Ltd falling/rising?

As of 09-Aug, Sakar Healthcare Ltd's stock price is rising to 924.65, driven by a 120.13% net profit increase and consistent positive results over seven quarters. The stock has outperformed the Sensex and shows strong long-term returns, indicating robust investor confidence despite a slight decline in participation.

As of 09-Aug, Sakar Healthcare Ltd's stock price is rising, currently at 924.65, reflecting an increase of 4.95 (0.54%). This upward movement can be attributed to several positive factors. The company has demonstrated significant financial growth, with a net profit increase of 120.13% and consistent positive results over the last seven consecutive quarters. Additionally, the stock has outperformed the benchmark Sensex, showing a 12.30% increase over the past month compared to the Sensex's 0.70% rise. <BR><BR>The stock's performance is also notable in the long term, with a remarkable 174.42% return over the past year, significantly surpassing the BSE500 index. Furthermore, Sakar Healthcare is trading above its moving averages across various time frames, indicating strong momentum. Despite a slight decline in investor participation, the high institutional holdings at 23.51% suggest confidence from more knowledgeable investors, which can positively influence the stock's performance. Overall, these factors contribute to the stock's rising price.

Which are the latest news on Sakar Healthcare?

Should I buy, sell or hold Sakar Healthcare Ltd?

Are Sakar Healthcare Ltd latest results good or bad?

Sakar Healthcare Ltd's latest results show strong revenue growth of 38.36% and a net profit increase of 120.13% year-on-year; however, profitability concerns arise from a 6.72% decline in net profit compared to the previous quarter and significant drops in operating and PAT margins. Investors should watch for how the company manages these margin pressures.

Sakar Healthcare Ltd's latest results present a mixed picture. On one hand, the company reported a significant year-on-year net profit growth of 120.13%, reaching ₹10.28 crore, and a robust revenue increase of 38.36%, with sales hitting an all-time quarterly high of ₹72.97 crore. This marks the seventh consecutive quarter of revenue growth, which is impressive and indicates strong market performance.<BR><BR>However, there are notable concerns regarding profitability. The net profit decreased by 6.72% compared to the previous quarter, and both the operating margin and PAT margin saw significant declines. The operating margin fell to 29.11% from 36.91% in the previous quarter, reflecting a 773 basis point contraction, while the PAT margin decreased to 14.09% from 15.50%. This margin erosion suggests rising operational challenges that could affect future profitability.<BR><BR>Overall, while the top-line growth is commendable, the decline in margins raises questions about the sustainability of this growth. Investors may need to monitor how the company addresses these margin pressures moving forward.

What does Sakar Healthcare do?

Sakar Healthcare Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2004 and publicly listed since 2015, reporting net sales of 71 Cr and a net profit of 11 Cr for March 2026. Key metrics include a P/E of 61.00 and a market cap of INR 1,847 Cr.

Overview:<BR>Sakar Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Sakar Healthcare Limited was incorporated as a Private Limited Company on March 26, 2004, and was converted into a Public Limited Company on March 27, 2015. The latest quarterly results report net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 71 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 11 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,847 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 61.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.17 <BR>Return on Equity: 9.39% <BR>Price to Book: 5.58 <BR><BR>Contact Details:<BR>Address: 10/13 Nr MN Desai Petrol Pump, Sarkhej Bavla Highway Changodar Gujarat : 382213 <BR>Tel: 91-2717-250477 <BR>Email: info@sakarhealthcare.com <BR>Website: http://www.sakarhealthcare.com

How big is Sakar Healthcare?

As of 10th June, Sakar Healthcare Ltd has a market capitalization of 1,847.00 Cr, with recent net sales of 251.74 Cr and a net profit of 30.48 Cr. Shareholder's funds are 285.48 Cr, and total assets amount to 415.26 Cr.

As of 10th June, Sakar Healthcare Ltd has a market capitalization of 1,847.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Sakar Healthcare reported Net Sales of 251.74 Cr and a Net Profit of 30.48 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 285.48 Cr and Total Assets of 415.26 Cr.

Who are in the management team of Sakar Healthcare?

The management team of Sakar Healthcare includes Sanjay S Shah (Chairman & Managing Director), Aarsh S Shah (Joint Managing Director), Ritaben S Shah (Whole-time Director), and three Independent Non-Executive Directors: Shailesh B Patel, Prashant C Srivastav, and Hemendrakumar C Shah. They oversee the company's operations and strategic direction.

The management team of Sakar Healthcare includes the following individuals:<BR><BR>1. **Sanjay S Shah** - Chairman & Managing Director<BR>2. **Aarsh S Shah** - Joint Managing Director<BR>3. **Ritaben S Shah** - Whole-time Director<BR>4. **Shailesh B Patel** - Independent Non-Executive Director<BR>5. **Prashant C Srivastav** - Independent Non-Executive Director<BR>6. **Hemendrakumar C Shah** - Independent Non-Executive Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the Sakar Healthcare?

Sakar Healthcare's peers include Kwality Pharma, Venus Remedies, Hikal, Indoco Remedies, NGL Fine Chem, Windlas Biotech, Amrutanjan Healt, Hester Bios, and Beta Drugs Ltd. Sakar Healthcare has an average management risk and a 1-year return of 165.81%, which is positive compared to its peers.

Peers: The peers of Sakar Healthcare are Kwality Pharma, Venus Remedies, Hikal, Indoco Remedies, NGL Fine Chem, Windlas Biotech, Amrutanjan Healt, Hester Bios, and Beta Drugs Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Venus Remedies and Amrutanjan Healt, while Average management risk is found at Kwality Pharma, Hikal, Indoco Remedies, Sakar Healthcare, NGL Fine Chem, Windlas Biotech, Hester Bios, and Beta Drugs Ltd, and the rest. Growth is rated as Good for Venus Remedies, Average for Sakar Healthcare, Kwality Pharma, and Beta Drugs Ltd, and Below Average for Hikal, Indoco Remedies, NGL Fine Chem, Windlas Biotech, and Hester Bios, and the rest. Capital Structure is Excellent for Kwality Pharma, Venus Remedies, NGL Fine Chem, Windlas Biotech, and Amrutanjan Healt, while Average is seen at Sakar Healthcare, and Below Average at Hikal, Indoco Remedies, and Hester Bios, and the rest.<BR><BR>Return Snapshot: Venus Remedies has the highest 1-year return at 269.84%, while Hikal has the lowest at -52.39%. Sakar Healthcare's 1-year return of 165.81% is significantly positive compared to its peers. Additionally, Windlas Biotech and Amrutanjan Healt have negative six-month returns.

Is Sakar Healthcare overvalued or undervalued?

As of November 27, 2025, Sakar Healthcare is considered very expensive and overvalued, with a PE Ratio of 42.16 and other key ratios significantly higher than industry norms, indicating it may not be a favorable investment despite strong recent performance.

As of 27 November 2025, Sakar Healthcare's valuation grade has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios supporting this assessment include a PE Ratio of 42.16, an EV to EBIT of 30.26, and a Price to Book Value of 2.72, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Sakar Healthcare's PE Ratio is notably higher than Sun Pharma's 37.62 and Cipla's 22.67, which are categorized as expensive and attractive, respectively. Additionally, the company's EV to EBITDA of 17.37 is also elevated compared to the industry average. Despite a strong performance relative to the Sensex over the past year, with a return of 27.04% versus the Sensex's 7.99%, the current valuation suggests that Sakar Healthcare may not offer a favorable investment opportunity at this time.

Is Sakar Healthcare technically bullish or bearish?

As of November 27, 2025, the technical trend is bullish with strong indicators like MACD and moving averages supporting this view, despite some mildly bearish signals from Dow Theory and OBV on the weekly chart.

As of 27 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and the moving averages on the daily chart confirm a bullish trend. The Bollinger Bands indicate a bullish condition on the monthly and mildly bullish on the weekly. The KST is also bullish on both time frames. However, the Dow Theory shows a mildly bearish signal on the weekly but is mildly bullish on the monthly, and the OBV reflects a similar mildly bearish stance on the weekly while being mildly bullish on the monthly. Overall, the strength of the bullish trend is reinforced by the positive performance against the Sensex over multiple time frames, particularly the 1Y and 5Y returns.

How has been the historical performance of Sakar Healthcare?

Sakar Healthcare has shown consistent growth over the past five years, with net sales increasing from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25, and profit after tax rising from 10.68 Cr to 17.50 Cr. The company's total assets also expanded significantly, from 115.04 Cr in Mar'20 to 415.26 Cr in Mar'25, indicating strong financial performance.

Answer:<BR>The historical performance of Sakar Healthcare shows a consistent growth trajectory in net sales and profitability over the past five years.<BR><BR>Breakdown:<BR>Sakar Healthcare's net sales have increased from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25, demonstrating a strong upward trend. Total operating income has followed a similar pattern, rising from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25. The company's total expenditure has also grown, reaching 127.90 Cr in Mar'25, up from 72.14 Cr in Mar'21, primarily driven by rising raw material costs and employee expenses. Operating profit (PBDIT) has improved significantly, from 22.60 Cr in Mar'21 to 49.68 Cr in Mar'25, indicating enhanced operational efficiency. Profit before tax has increased from 13.23 Cr in Mar'21 to 21.53 Cr in Mar'25, while profit after tax has risen from 10.68 Cr in Mar'21 to 17.50 Cr in Mar'25. The company's earnings per share (EPS) have also shown growth, climbing from 6.84 in Mar'21 to 7.97 in Mar'25. On the balance sheet, total assets have expanded from 115.04 Cr in Mar'20 to 415.26 Cr in Mar'25, reflecting robust growth in shareholder's funds and reserves. Overall, Sakar Healthcare has demonstrated a solid financial performance with increasing revenues, profits, and asset growth over the years.

Who are the top shareholders of the Sakar Healthcare?

The top shareholders of Sakar Healthcare include Sanjay S Shah with 45.6%, Tata Capital Healthcare Fund II at 10.52%, and Foreign Institutional Investors holding 13.61%. Individual investors own 15.94%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Sakar Healthcare include the promoters, with Sanjay S Shah holding the largest share at 45.6%. Additionally, Tata Capital Healthcare Fund II is the highest public shareholder, owning 10.52%. Foreign Institutional Investors (FIIs) hold a combined 13.61% of the company through four different FIIs. Individual investors collectively own 15.94% of the shares. There are no pledged promoter holdings, and mutual funds do not currently hold any shares in the company.

When is the next results date for Sakar Healthcare?

No Upcoming Board Meetings

Has Sakar Healthcare declared dividend?

No Dividend History Available